2m 2m 2m 2m 2m 2m 2m
CONTINEUM THE-A (CTNM)
NASDAQ
$12.47+$0.09 (+0.73%)
Price as of Jun 03, 2026 4:04 PM EDT- $441.4MMarket Cap
- 161.18%1-Year Change
- BiotechnologyIndustry
CONTINEUM THE-A (CTNM)
$12.47+$0.09 (+0.73%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | ||
|---|---|---|---|
Income Statement | |||
Total Operating Revenue | N/A N/A | 0 N/A | |
Cost of Revenue | N/A N/A | N/A N/A | |
Gross Profit | 0 N/A | 0 N/A | |
Sales and Marketing Expense | N/A N/A | N/A N/A | |
Research and Development Expense | -51.5M +34.10% | -38.4M N/A | |
Depreciation and Amortization Expense | 323,000 +25.19% | 258,000 N/A | |
Total Operating Expenses | 68.1M +33.73% | 50.9M N/A | |
Operating Profit | -68.1M +33.73% | -50.9M N/A | |
Interest Income | 8.2M -7.40% | 8.9M N/A | |
Interest Expense | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 8.2M -7.40% | 8.9M N/A | |
Total Nonoperating Income and Expense | 8.1M -6.43% | 8.6M N/A | |
Income before Taxes | -68.1M +61.06% | -42.3M N/A | |
Income Taxes | 0 N/A | 0 N/A | |
Extraordinary Items | N/A N/A | N/A N/A | |
Net Income | -60.0M +41.93% | -42.3M N/A | |
Net Income from Continuing Operations Applicable to Common | -60.0M +41.93% | -42.3M N/A | |
Basic EPS and Net Income | -2.17 -0.46% | -2.18 N/A | |
Diluted EPS and Net Income | -2.17 -0.46% | -2.18 N/A | |
Basic Weighted Average Shares | 27.7M +43.14% | 19.4M N/A | |
Diluted Weighted Average Shares | 27.7M +43.14% | 19.4M N/A | |
Balance Sheet | |||
Cash and Cash Equivalents | 75.6M +244.54% | 21.9M N/A | |
Short-Term Investments | 187.3M +2.45% | 182.8M N/A | |
Cash and Cash Equivalents and Short-Term Investments | 262.9M +28.39% | 204.8M N/A | |
Total Current Assets | 267.9M +29.81% | 206.4M N/A | |
Accumulated Depreciation | 2.0M +14.33% | 1.7M N/A | |
Property and Plant and Equipment and Net | 830,000 -16.08% | 989,000 N/A | |
Total Long-Term Assets | 256,000 +8,433.33% | 3,000 N/A | |
Total Assets | 276.6M +29.97% | 212.8M N/A | |
Income Taxes Payable | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | |
Total Current Liabilities | 9.7M -2.31% | 10.0M N/A | |
Total Long-Term Debt | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 5.9M N/A | 0 N/A | |
Total Liabilities | 15.7M +5.90% | 14.8M N/A | |
Retained Earnings | -177.4M +51.09% | -117.4M N/A | |
Total Stockholders Equity | 261.0M +31.77% | 198.1M N/A | |
Total Shares Outstanding | 31.2M +20.82% | 25.9M N/A | |
Cash Flow | |||
Cash from Operating Activities | -55.3M +68.40% | -32.8M N/A | |
Capital Expenditures | 231,000 -55.06% | 514,000 N/A | |
Cash from Investing Activities | -3.7M -94.68% | -69.7M N/A | |
Dividends Paid | N/A N/A | N/A N/A | |
Cash from Financing Activities | 112.7M +3.38% | 109.0M N/A | |
Financials Ratio | |||
Gross Margin | N/A N/A | N/A N/A | |
Operating Margin | N/A N/A | N/A N/A | |
Return on Assets | -24.51% N/A | N/A N/A | |
Return on Equity | -26.13% N/A | N/A N/A | |
Revenue Growth | N/A N/A | N/A N/A | |
Current Ratio | 27.50 N/A | N/A N/A | |
Cash Ratio | 7.76 N/A | N/A N/A | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow